Pharmacoeconomics and Safe Medication Use
Pharmacoeconomics
Agency for Healthcare Research and Quality. Quality
indicators toolkit. Toolkit for Using the AHRQ Quality
Indicators | Agency for Healthcare Research and Quality
Bootman JL, Townsend RJ, McGhan WF. Principles of
Pharmacoeconomics. 3rd ed. Harvey Whitney Books;
2004.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL,
Torrance GW. Methods for the Economic Evaluation
of Health Care Programmes. 4th ed. Oxford University
Press; 2015.
Ernst FR, Levy H, Qualy RL. Simplified pharma-
coeconomics of critical care and severe sepsis. J
org/10.1177/0885066607304231
Grauer
DW,
Lee
J,
Odom
TD,
et
al,
eds.
Pharmacoeconomics and Outcomes: Applications for
Patient Care. 2nd ed. American College of Clinical
Pharmacy; 2003.
Jo C. Cost-of-illness studies: concepts, scopes, and
methods. Clin Mol Hepatol. 2014;20(4):327-337. https://
doi.org/10.3350/cmh.2014.20.4.327
Lat I, Paciullo C, Daley MJ, et al. Position paper on
Med.
2020;48(9):e813-e834.
https://doi.org/10.1097/
ccm.0000000000004437
Robinson A, Gyrd-Hansen D, Bacon P, et al. Estimating
a WTP-based value of a QALY: the “chained” approach.
Soc Sci Med. 2013;92:92-104. https://doi.org/10.1016/j.
socscimed.2013.05.013
Medication Errors, Adverse Drug Reactions,
Adverse Drug Events, and Side Effects
Bates DW, Cullen DJ, Laird N, et al. Incidence of
adverse drug events and potential adverse drug events.
Implications for prevention. ADE Prevention Study
Bates DW, Levine DM, Salmasian H, et al. The safety
of inpatient health care. N Engl J Med. 2023;388(2):142-
153. https://doi.org/10.1056/nejmsa2206117
Billstein-Leber M, Carrillo CJD, Cassano AT, Moline
K, Robertson JJ. ASHP guidelines on preventing
2018;75(19):1493-1517.
https://doi.org/10.2146/
ajhp170811
Centers for Medicare & Medicaid Services. Medicaid
Promoting Interoperability Program Modified Stage 2
Eligible Professionals Objectives and Measures for 2018
Objective 7 of 10 Updated: July 2018
Centers for Medicare & Medicaid Services. Medicaid
EHR Incentive Program Health Information Exchange
Objective Stage 3
Danan G, Benichou C. Causality assessment of
adverse reactions to drugs. I. A novel method based
on the conclusions of international consensus meet-
ings: application to drug-induced liver injuries. J
Clin Epidemiol. 1993;46(11):1323-1330. https://doi.
org/10.1016/0895-4356(93)90101-6
Haerdtlein A, Debold E, Rottenkolber M, et al. Which
adverse events and which drugs are implicated in drug-
related hospital admissions? A systematic review and
meta-analysis. J Clin Med. 2023;12(4):1320. https://doi.
org/10.3390/jcm12041320
Hakkarainen KM, Hedna K, Petzold M, Hägg S.
Percentage of patients with preventable adverse drug
reactions and preventability of adverse drug reactions—
a meta-analysis. PLoS One. 2012;7(3):e33236. https://doi.
org/10.1371/journal.pone.0033236
Hassan E, Badawi O, Weber RJ, Cohen H. Using tech-
nology to prevent adverse drug events in the intensive
https://doi.org/10.1097/ccm.0b013e3181dde1b4
Kane-Gill SL, Buckley MS. Medication safety and
active surveillance. In: Erstad BL, ed. Critical Care
Pharmacy; 2016:971-982.
Kane-Gill SL, Jacobi J, Rothschild JM. Adverse drug
events in intensive care units: risk factors, impact, and the
S89. https://doi.org/10.1097/ccm.0b013e3181dd8364
Karch FE, Lasagna L. Adverse drug reactions. A critical
Koppel R, Metlay JP, Cohen A, et al. Role of comput-
erized physician order entry systems in facilitating